Back to Search Start Over

Tryptophan 2,3-dioxygenase expression identified in human hepatocellular carcinoma cells and in intratumoral pericytes of most cancers

Authors :
Aurélie Daumerie
Simon Klaessens
Etienne Marbaix
Vincent Stroobant
Benoît Van den Eynde
Tereza Dvorakova
Caroline Bouzin
Marie-Claire Letellier
Julie Lelotte
Jean-Christophe Renauld
Marie Solvay
Delia Hoffmann
Nicolas van Baren
UCL - SSS/DDUV - Institut de Duve
UCL - SSS/DDUV/CELL - Biologie cellulaire
UCL - SSS/DDUV/GECE - Génétique cellulaire
UCL - SSS/DDUV/MEXP - Médecine expérimentale
UCL - SSS/IREC - Institut de recherche expérimentale et clinique
UCL - (SLuc) Service d'anatomie pathologique
UCL - (SLuc) Unité d'oncologie médicale
Source :
Cancer immunology research, Vol. 8, no. 1, p. 19-31 (2020)
Publication Year :
2019
Publisher :
American Association for Cancer Research, 2019.

Abstract

Tryptophan catabolism is used by tumors to resist immune attack. It can be catalyzed by indoleamine 2,3-dioxygenase (IDO1) and tryptophan 2,3-dioxygenase (TDO). IDO1 is frequently expressed in tumors and has been widely studied as a potential therapeutic target to reduce resistance to cancer immunotherapy. In contrast, TDO expression in tumors is not well characterized. Several human tumor cell lines constitutively express enzymatically active TDO. In human tumor samples, TDO expression has previously been detected by transcriptomics, but the lack of validated antibodies has precluded detection of the TDO protein and identification of TDO-expressing cells. Here, we developed novel TDO-specific monoclonal antibodies and confirmed by immunohistochemistry the expression of TDO in the majority of human cancers. In all hepatocarcinomas (10/10), TDO was expressed by most tumor cells. Some glioblastomas (10/39) and kidney carcinomas (1/10) also expressed TDO in tumor cells themselves but only in focal tumor areas. In addition, all cancers tested contained foci of nontumoral TDO-expressing cells, which were identified as pericytes by their expression of PDGFRβ and their location in vascular structures. These TDO-expressing pericytes belonged to morphologically abnormal tumor vessels and were found in high-grade tumors in the vicinity of necrotic or hemorrhagic areas, which were characterized by neoangiogenesis. We observed similar TDO-expressing pericytes in inflammatory pulmonary lesions containing granulation tissue, and in chorionic villi, two tissue types that also feature neoangiogenesis. Our results confirm TDO as a relevant immunotherapeutic target in hepatocellular carcinoma and suggest a proangiogenic role of TDO in other cancer types.See article by Schramme et al., p. 32. ispartof: Cancer Immunology Research vol:8 issue:1 pages:19-31 ispartof: location:United States status: published

Details

Language :
English
Database :
OpenAIRE
Journal :
Cancer immunology research, Vol. 8, no. 1, p. 19-31 (2020)
Accession number :
edsair.doi.dedup.....e0c5abee8ed6c72659fa34257e4b0fea